Treatment of adults with clinically suspected severe thrombotic thrombocytopenic purpura - Experiences of a single centre

Transfusion Medicine and Hemotherapy

Volumn 34, Issue 1, 2007, Pages 64-72

  Zeitler, H ^a,b   Ulrich Merzenich, G ^a   Walger, P ^a   Bartels, M ^a   Goldmann, G ^b   Vetter, H ^a   Oldenburg, J ^b  

^a Centre of Extracorporeal Treatment and Autoimmunity (CETA)   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Immunotolerance; Plasma exchange; TTP

Indexed keywords

AZATHIOPRINE; CLEMASTINE FUMARATE; DOPAMINE; FRESH FROZEN PLASMA; GLUCONATE CALCIUM; HEPARIN; PREDNISOLONE; STEROID;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CATHETER OCCLUSION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FEMALE; FLUID THERAPY; FOLLOW UP; HEART ARREST; HEART TAMPONADE; HUMAN; HYPOTENSION; HYPOXIA; JUGULAR VEIN; LOW DRUG DOSE; MALE; PARESTHESIA; PLASMAPHERESIS; PNEUMOTHORAX; PREMEDICATION; RETROPERITONEAL HEMORRHAGE; SAMPLE SIZE; SEPSIS; SERUM SICKNESS; TETANY; THERAPY EFFECT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URTICARIA; VASCULAR ACCESS; VOMITING;

EID: 33846578225     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097626     Document Type: Article

References (34)

1. Zheng LX, Kaufman RM, Goodnough T, Sadler JE: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049.
2. George JN: The Oklahoma Thrombotic Thrombocytopenis Purpura Hemolytic Uremic Syndrome Registry. Transfusion 2003;44:1384-1392.
3. Allford SL, Hunt BJ, Rose P, Machin SJ: Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556-573.
4. Pene F, Vigneau C, Auburtin M, Moreau D, Zahar JR, Coste J, Heshmati F, Mira JP: Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med 2005;31:71-78.
5. George JN: Thrombotic thrombocytopenic purpura. N Eng J Med 2006;354:1927-1935.
6. Veyradier A, Meyer D: Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 2005;3:2420-2427.
7. Rock G: The management of thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2005;31:709-716.
8. Fontana S, Hovinga JA, Studt JD, Alberio L, Lammle B, Taleghani BM: Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol 2004;41:48-59.
9. Barandenko N, Brecher ME: United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicentre survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis 1998;13:133-141.
10. Manucci PM: Thrombotic thrombocytopenic purpura: another example of immunomediated thrombosis. Pathophysiol Haemost Thromb 2006;35:89-97.
11. Sadler JE, Moake JL, Miyata T, George JN: Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004;407-423.
12. Plaimauer B, Scheiflinger F: Expression and characterization of recombinant human ADAMTS13. Semin Hematol 2004;41:24-33.
13. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, Gilcher GO: Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. Transfusion 2000;40:897-901.
14. McMinn IA, Thomas DR, Terrell C, Duvall D, Veseley S, George JN: Complications of plasma exchange in thrombotic thrombocytopenic purpura haemolytic uremic syndrome a study of 78 additional patients. Transfusion 2003;43:415-416.
15. Yeo F, Bohen EM, Yuan CM, Sawyers ES, Abbott KC: Therapeutic plasma exchange as a nephrological procedure: a single-centre experience. J Clin Apheresis 2005;20:208-216.
16. Zeitler H, Ulrich-Merzenich G, Hess L: Treatment of acquired hemophilia by the Bonn-Malmö protocol: documentation of an in vivo immunomodulating concept. Blood 2005;105:2287-2293.
17. Zeitler H, Ulrich-Merzenich G, Walger P, Düsing R, Vetter H, Brackmann HH: Das modifizierte Bonn-Malmö-Protokoll in der Behandlung der erworbenen Hemmkörper-hämophilie. Eine multimodale Therapiestrategie. Dtsch Med Wochenschr 2006;131:141-147.
18. Zeitler H, Ulrich-Merzenich G, Walger P, Vetter H, Oldenburg J, Goldmann G, Brackmann H-H: Treatment of factor VIII inhibitors with selective IgG immunoadsorption - a single center experience in 50 patients with acquired hemophilia. Transfus Med Hemother 2006;33:160-164.
19. Tesdale G, Jenett B: Assessment of coma and impaired consciousness a practical scale. Lancet 1974;ii:81-84.
20. Gann M, Sardi A: Improved results using ultrasound guidance for central venous access. Am Surg 2003;12:1104-1107.
21. Vesely S, JN George, Lämmle B, Studt JD, Alberio L,MA Harake, Raskop GE: ADAMTS13 Activity in thrombotic thrombopenic purpura haemolytic uremic syndrome: relation to presenting features and clinical outcome in142 patients. Blood 2003;102:56-68.
22. Tsai HM: Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-1081.
23. Shenkman B: The role of ADAMTS-13 in platelet adhesion in flow: methods for diagnosis of thrombotic thrombocytopenic purpura. Pathophysiol Haemost Thromb 2006;35:98-102.
24. Moake JL: Thrombotic microangiopathies. N Eng J Med 2002;347:589-600.
25. Stahl D: Current concepts on the immune regulation: impact on scientific and clinical aspects of immunohematology. Trans Med Hemother 2005;32:293-295.
26. Miller J: Principles of immunological tolerance. Trans Med Hemother 2005;32:322-331.
27. Scheiflinger F, Knöbl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M: Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003;102:3241-3243.
28. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005;115:2752-2761.
29. Allfort SL, Harrison P, Lawrie AS, Liesner R, Mackie I, Machin SJ: von Willebrand factor cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000;11:1215-1222.
30. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N: Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant in the treatment of thrombotic thrombocytopenic purpura. J Clin Apheresis 2001;16:134-138.
31. Perdue JJ, Chandler LK, Vesely SK: Unintentional platelet removal by plasmapheresis J Clin Apheresis 2001;16:55-60.
32. Burgstaler EA, Pineda AA: Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs Cobe Spectra. J Clin Apheresis 2001;16:61-66.
33. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U: High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001;114:114-120.
34. Kuwahara-Watanbe K, Hidai C, Ikeda H, Aoka Y, Ihikawa K, Iguchi N, Okada-Ohno M, Yokota J, Kasanuki H, Kawana M: Heparin regulates transcription of endothelin-1 gene in endothelial cells. J Vasc Res 2005;42:183-189.